BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, Parikh ND, Browning T, Singal AG. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77. [PMID: 27862091 DOI: 10.1111/apt.13841] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
2 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
3 Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C. Should Patients With NAFLD/NASH Be Surveyed for HCC? Transplantation 2019;103:39-44. [DOI: 10.1097/tp.0000000000002361] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
4 Fujiwara N, Liu P, Athuluri-divakar SK, Zhu S, Hoshida Y. Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 3-25. [DOI: 10.1007/978-3-030-21540-8_1] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00337-6. [PMID: 34294580 DOI: 10.1016/j.dld.2021.06.023] [Reference Citation Analysis]
6 Vietti Violi N, Fowler KJ, Sirlin CB, Taouli B. Abbreviated Magnetic Resonance Imaging for HCC Surveillance. Clin Liver Dis (Hoboken) 2021;17:133-8. [PMID: 33868653 DOI: 10.1002/cld.1016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Singal AG, Murphy CC. Hepatocellular Carcinoma Surveillance: An Effective But Complex Process. Gastroenterology 2019;156:1215. [PMID: 30543799 DOI: 10.1053/j.gastro.2018.08.066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Singal AG, Patibandla S, Obi J, Fullington H, Parikh ND, Yopp AC, Marrero JA. Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1925-1932.e1. [PMID: 32920214 DOI: 10.1016/j.cgh.2020.09.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Singal AG. Reply. Gastroenterology 2019;157:901-2. [PMID: 31306633 DOI: 10.1053/j.gastro.2019.07.011] [Reference Citation Analysis]
10 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
11 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
13 Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2020:S1076-6332(20)30354-8. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Jun TW, Yeh ML, Yang JD, Chen VL, Nguyen P, Giama NH, Huang CF, Hsing AW, Dai CY, Huang JF, Chuang WL, Roberts LR, Yu ML, Nguyen MH. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int 2018;38:895-902. [PMID: 29045023 DOI: 10.1111/liv.13613] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
15 Hernandez-Meza G, Violi NV, Said D, Novogrodsky E, Villavisanis D, Maron SZ, Frere J, Schiano TD, Friedman S, Boffetta P, Branch A, Taouli B. MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center. Abdom Radiol (NY) 2021. [PMID: 34283266 DOI: 10.1007/s00261-021-03212-7] [Reference Citation Analysis]
16 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
17 Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol 2019;18:810-5. [PMID: 31543467 DOI: 10.1016/j.aohep.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
18 Best J, Bechmann LP, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2020;18:728-735.e4. [DOI: 10.1016/j.cgh.2019.11.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 18.5] [Reference Citation Analysis]
19 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
20 Rich NE, Singal AG. Reply. Gastroenterology 2018;155:1275-6. [PMID: 30236560 DOI: 10.1053/j.gastro.2018.09.026] [Reference Citation Analysis]
21 Park HJ, Kim SY, Singal AG, Lee SJ, Won HJ, Byun JH, Choi SH, Yokoo T, Kim MJ, Lim YS. Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. Liver Int 2021. [PMID: 34817921 DOI: 10.1111/liv.15110] [Reference Citation Analysis]
22 Rich NE, Parikh ND, Singal AG. Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. Semin Liver Dis 2017;37:296-304. [PMID: 29272892 DOI: 10.1055/s-0037-1608775] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
23 Millet JD, Kamaya A, Choi HH, Dahiya N, Murphy PM, Naveed MZ, O’boyle M, Parra LA, Perez MG, Pirmoazen AM, Rodgers SK, Wasnik AP, Maturen KE. ACR Ultrasound Liver Reporting and Data System: Multicenter Assessment of Clinical Performance at One Year. Journal of the American College of Radiology 2019;16:1656-62. [DOI: 10.1016/j.jacr.2019.05.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
24 Yamamoto Y, Kondo S, Matsuzaki J, Esaki M, Okusaka T, Shimada K, Murakami Y, Enomoto M, Tamori A, Kato K, Aoki Y, Takizawa S, Sakamoto H, Niida S, Takeshita F, Ochiya T. Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease. Hepatol Commun. 2020;4:284-297. [PMID: 32025611 DOI: 10.1002/hep4.1451] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
25 Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00866-1. [PMID: 34391922 DOI: 10.1016/j.cgh.2021.08.010] [Reference Citation Analysis]
26 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2021:S0168-8278(21)02026-2. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Reference Citation Analysis]
27 Singal AG, Ioannou GN. For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective? Clin Gastroenterol Hepatol 2019;17:1732-5. [PMID: 30772587 DOI: 10.1016/j.cgh.2019.02.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
28 Olson MC, Vietti Violi N, Taouli B, Venkatesh SK. Abbreviated Magnetic Resonance Imaging Protocols in the Abdomen and Pelvis. Magn Reson Imaging Clin N Am 2020;28:381-94. [PMID: 32624156 DOI: 10.1016/j.mric.2020.03.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl 2018;24:1171-7. [PMID: 29781162 DOI: 10.1002/lt.25202] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
30 Lim J, Singal AG. Surveillance and Diagnosis of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;13:2-5. [PMID: 30911378 DOI: 10.1002/cld.761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
31 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
32 Kim JH, Kang SH, Lee M, Choi HS, Jun BG, Kim TS, Choi DH, Suk KT, Kim MY, Kim YD, Cheon GJ, Baik SK, Kim DJ. Improved detection of hepatocellular carcinoma by dynamic computed tomography in cirrhotic patients with chronic hepatitis B: A multicenter study. J Gastroenterol Hepatol 2020;35:1795-803. [PMID: 32222111 DOI: 10.1111/jgh.15046] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
34 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
35 Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31297-0. [PMID: 32961340 DOI: 10.1016/j.cgh.2020.09.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
36 Qian Y, Wang JW, Fang Y, Yuan XD, Fan YC, Gao S, Wang K. Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. Med Sci Monit 2020;26:e927444. [PMID: 33320844 DOI: 10.12659/MSM.927444] [Reference Citation Analysis]
37 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
38 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
39 Fetzer DT, Rodgers SK, Harris AC, Kono Y, Wasnik AP, Kamaya A, Sirlin C. Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System. Radiol Clin North Am 2017;55:1197-209. [PMID: 28991560 DOI: 10.1016/j.rcl.2017.06.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
40 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Long XR, Zhang YJ, Zhang MY, Chen K, Zheng XFS, Wang HY. Identification of an 88-microRNA signature in whole blood for diagnosis of hepatocellular carcinoma and other chronic liver diseases. Aging (Albany NY). 2017;9:1565-1584. [PMID: 28657540 DOI: 10.18632/aging.101253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Singal AG, Mittal S, Yerokun OA, Ahn C, Marrero JA, Yopp AC, Parikh ND, Scaglione SJ. Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. Am J Med. 2017;130:1099-1106.e1. [PMID: 28213044 DOI: 10.1016/j.amjmed.2017.01.021] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
43 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
44 Bottenus N, Pinton GF, Trahey G. The Impact of Acoustic Clutter on Large Array Abdominal Imaging. IEEE Trans Ultrason Ferroelectr Freq Control 2020;67:703-14. [PMID: 31715564 DOI: 10.1109/TUFFC.2019.2952797] [Reference Citation Analysis]
45 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
46 Choi HH, Perez MG, Millet JD, Liang T, Wasnik AP, Maturen KE, Kamaya A. Association of advanced hepatic fibrosis and sonographic visualization score: a dual-center study using ACR US LI-RADS. Abdom Radiol 2019;44:1415-22. [DOI: 10.1007/s00261-018-1862-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
47 Kutaiba N, Archard R. Ultrasound liver imaging reporting and data system ® : Considerations for routine practice. Australasian Journal of Ultrasound in Medicine 2018;21:201-3. [DOI: 10.1002/ajum.12107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Lu F, Shah PA, Rao A, Gifford-Hollingsworth C, Chen A, Trey G, Soryal M, Talat A, Aslam A, Nasir B, Choudhry S, Ishtiaq R, Sanoff H, Conteh LF, Noonan A, Hu KQ, Schmidt C, Fu M, Civan J, Xiao G, Lau DT, Lu X. Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00271. [PMID: 33512798 DOI: 10.14309/ctg.0000000000000271] [Reference Citation Analysis]
49 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
50 Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90. [PMID: 31593481 DOI: 10.1080/00365521.2019.1673478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
51 Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? WJH 2022; 14(2):354-71. [DOI: 10.4254/wjh.v14.i2.354] [Reference Citation Analysis]
52 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
53 Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP, Beg MS, Singh S. Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis. Am J Clin Oncol 2018;41:874-81. [PMID: 28537989 DOI: 10.1097/COC.0000000000000388] [Cited by in Crossref: 53] [Cited by in F6Publishing: 12] [Article Influence: 17.7] [Reference Citation Analysis]
54 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Lin N, Lin Y, Xu J, Liu D, Li D, Meng H, Gallant MA, Kubota N, Roy D, Li JS, Gorospe EC, Sherman M, Gish RG, Abou-Alfa GK, Nguyen MH, Taggart DJ, Van Etten RA, Hoshida Y, Li W. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol Commun 2022. [PMID: 35244350 DOI: 10.1002/hep4.1918] [Reference Citation Analysis]
57 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718. e1. [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064] [Cited by in Crossref: 242] [Cited by in F6Publishing: 236] [Article Influence: 60.5] [Reference Citation Analysis]
58 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY) 2021;46:969-78. [PMID: 32951065 DOI: 10.1007/s00261-020-02771-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, Murphy C, McCallister K, Singal AG. Reply. Hepatology 2017;66:1002-3. [PMID: 28543272 DOI: 10.1002/hep.29286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. Liver Transpl 2019;25:369-79. [PMID: 30582779 DOI: 10.1002/lt.25398] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
62 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 1057] [Article Influence: 375.3] [Reference Citation Analysis]
63 Issa D, Alkhouri N. Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history. Hepatobiliary Surg Nutr 2017;6:401-3. [PMID: 29312975 DOI: 10.21037/hbsn.2017.07.07] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
64 Parikh ND. PRO: Hepatocellular Carcinoma Surveillance: A Useful Tool Against the Rising Tide of HCC. Am J Gastroenterol 2017;112:1632-3. [PMID: 28972597 DOI: 10.1038/ajg.2017.366] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
65 Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.023] [Reference Citation Analysis]
66 Khatri G, Pedrosa I, Ananthakrishnan L, Leon AD, Fetzer DT, Leyendecker J, Singal AG, Xi Y, Yopp A, Yokoo T. Abbreviated‐protocol screening MRI vs. complete‐protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI‐RADS v2018. J Magn Reson Imaging 2019;51:415-25. [DOI: 10.1002/jmri.26835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
67 Kim YY, An C, Kim DY, Aljoqiman KS, Choi JY, Kim MJ. Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits. Ultrasonography 2019;38:311-20. [PMID: 31079440 DOI: 10.14366/usg.18051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
68 Fetzer DT, Browning T, Xi Y, Yokoo T, Singal AG. Associations of Ultrasound LI-RADS Visualization Score With Examination-, Sonographer-, and Radiologist-Factors: Retrospective Assessment in Over 10,000 Examinations. AJR Am J Roentgenol 2021. [PMID: 34910539 DOI: 10.2214/AJR.21.26735] [Reference Citation Analysis]
69 Sevco TJ, Masch WR, Maturen KE, Mendiratta-Lala M, Wasnik AP, Millet JD. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol 2021;217:644-50. [PMID: 34259543 DOI: 10.2214/AJR.20.23447] [Reference Citation Analysis]
70 Kiri L, Abdolell M, Costa AF, Keough V, Rowe J, Butt R, Clarke SE. US LI-RADS Visualization Score: Interobserver Variability and Association With Cause of Liver Disease, Sex, and Body Mass Index. Can Assoc Radiol J 2021;:8465371211012104. [PMID: 33938768 DOI: 10.1177/08465371211012104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Gupta M, Gabriel H, Miller FH. Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2018;47:585-602. [DOI: 10.1016/j.gtc.2018.04.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
72 Patel D. Editorial: ultrasound surveillance of hepatocellular carcinoma in the 21st century. Aliment Pharmacol Ther 2017;45:561-2. [PMID: 28074512 DOI: 10.1111/apt.13891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
73 Jaffe A, Schilsky ML, Deshpande R, Batra R. Liver Transplantation in the Time of COVID19: Barriers and Ethical considerations for Management and Next Steps. Hepatol Commun. 2020;. [PMID: 32838103 DOI: 10.1002/hep4.1568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Reference Citation Analysis]
75 Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Parikh N, Browning T, Singal AG. Editorial: ultrasound surveillance of hepatocellular carcinoma in the 21st century - authors' reply. Aliment Pharmacol Ther 2017;45:562-3. [PMID: 28074510 DOI: 10.1111/apt.13910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Lima PH, Fan B, Bérubé J, Cerny M, Olivié D, Giard JM, Beauchemin C, Tang A. Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR Am J Roentgenol 2019;213:17-25. [PMID: 30995098 DOI: 10.2214/AJR.18.20341] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
77 Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc 2022:S0929-6646(22)00144-9. [PMID: 35450743 DOI: 10.1016/j.jfma.2022.04.001] [Reference Citation Analysis]
78 Fetzer DT. Beyond the AJR : Shorter Ultrasound Screening Intervals for Hepatocellular Carcinoma Improve Patient Outcomes. American Journal of Roentgenology. [DOI: 10.2214/ajr.21.26780] [Reference Citation Analysis]
79 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
80 Offerdahl K, Huber M, Long W, Bottenus N, Nelson R, Trahey G. Occult Regions of Suppressed Coherence in Liver B-Mode Images. Ultrasound Med Biol 2022;48:47-58. [PMID: 34702640 DOI: 10.1016/j.ultrasmedbio.2021.09.007] [Reference Citation Analysis]
81 Alenezi AO, Krishna S, Mendiratta-Lala M, Kielar AZ. Imaging and Management of Liver Cancer. Semin Ultrasound CT MR 2020;41:122-38. [PMID: 32446427 DOI: 10.1053/j.sult.2019.12.002] [Reference Citation Analysis]
82 Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Mancebo A, Varela M, González-diéguez ML, Navascués CA, Cadahía V, Mesa-álvarez A, Rodrigo L, Rodríguez M. Incidence and risk factors associated with hepatocellular carcinoma surveillance failure: Hepatocellular carcinoma surveillance. Journal of Gastroenterology and Hepatology 2018;33:1524-9. [DOI: 10.1111/jgh.14108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
85 Simmons OL, Feng Y, Parikh ND, Singal AG. Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2019;17:766-73. [PMID: 30056183 DOI: 10.1016/j.cgh.2018.07.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
86 Krampitz GW, Aloia TA. Staging of Biliary and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:663-83. [DOI: 10.1016/j.soc.2019.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
87 Tang A, Singal AG, Mitchell DG, Hecht EM, Fowler KJ, Kulik L, Parikh ND, Kono Y, Sirlin CB. Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2019;17:1228-38. [DOI: 10.1016/j.cgh.2018.10.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
88 Vipani A, Lauzon M, Luu M, Roberts LR, Singal AG, Yang JD. Decreasing Trend of Serum α-Fetoprotein Level in Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00867-3. [PMID: 34391921 DOI: 10.1016/j.cgh.2021.08.011] [Reference Citation Analysis]
89 Honap S, Oben JA. Fat and Hidden Liver Cancer. Clin Liver Dis (Hoboken) 2021;17:49-52. [PMID: 33680434 DOI: 10.1002/cld.1011] [Reference Citation Analysis]
90 Chang Y, Lee JH. Optimal Modalities for HCC Surveillance in a High-Incidence Region. Clin Liver Dis (Hoboken) 2020;16:236-9. [PMID: 33489094 DOI: 10.1002/cld.923] [Reference Citation Analysis]
91 Tzartzeva K, Singal AG. Testing for AFP in combination with ultrasound improves early liver cancer detection. Expert Rev Gastroenterol Hepatol. 2018;12:947-949. [PMID: 30118333 DOI: 10.1080/17474124.2018.1512855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
92 Carbonell G, Taouli B. Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer. Magn Reson Imaging Clin N Am 2021;29:321-7. [PMID: 34243920 DOI: 10.1016/j.mric.2021.05.003] [Reference Citation Analysis]
93 Nahon P, Ronot M. Repeating Ultrasound for Hepatocellular Carcinoma Detection in Case of Inadequate Liver Visualization: A Matter of Expertise. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00826-0. [PMID: 34358716 DOI: 10.1016/j.cgh.2021.07.044] [Reference Citation Analysis]
94 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
95 Dirchwolf M, Marciano S, Ruf AE, Singal AG, D'Ercole V, Coisson P, Zerega A, Orozco F, Palazzo A, Fassio E, Arufe D, Anders M, D'Amico C, Gaite L, Thompson M, Perez D, Haddad L, Demirdjian E, Zunino M, Gadano A, Murga MD, Bermudez C, Tomatis J, Grigera N, Antinucci F, Baravalle M, Gazari MMR, Ferreiro M, Barbero M, Curia A, Demonte M, Gualano G. Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice. Ann Hepatol 2021;25:100344. [PMID: 33819695 DOI: 10.1016/j.aohep.2021.100344] [Reference Citation Analysis]
96 Petrasek J, Singal AG, Rich NE. Harms of hepatocellular carcinoma surveillance. Curr Hepatol Rep 2019;18:383-9. [PMID: 33214987 DOI: 10.1007/s11901-019-00488-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Zhu J, Huang J, Zhang J, Chen Z, Lin Y, Grigorean G, Li L, Liu S, Singal AG, Parikh ND, Lubman DM. Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis. J Proteome Res. 2020;19:3452-3466. [PMID: 32412768 DOI: 10.1021/acs.jproteome.0c00270] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
98 Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2021. [PMID: 34618932 DOI: 10.1002/hep.32185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
100 Toyoda H, Hiraoka A, Olivares J, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, Singal AG. Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31491-9. [PMID: 33295281 DOI: 10.1016/j.cgh.2020.10.033] [Reference Citation Analysis]
101 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
102 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
103 Merchante N, Figueruela B, Rodríguez-Fernández M, Rodríguez-Arrondo F, Revollo B, Ibarra S, Galindo MJ, Merino E, Montero M, Téllez F, García-Deltoro M, Rivero-Juárez A, Delgado-Fernández M, Ríos-Villegas MJ, Aguirrebengoa K, García MA, Portu J, Vera-Méndez FJ, Villalobos M, Mínguez C, De Los Santos I, López-Ruz MA, Omar M, Galera C, Macias J, Pineda JA; GEHEP-002 Study Group. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. AIDS 2019;33:269-78. [PMID: 30325782 DOI: 10.1097/QAD.0000000000002065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, Murphy C, McCallister K, Singal AG. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017;65:1196-1205. [PMID: 27775821 DOI: 10.1002/hep.28895] [Cited by in Crossref: 97] [Cited by in F6Publishing: 96] [Article Influence: 16.2] [Reference Citation Analysis]
105 Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020;158:1822-30. [PMID: 32006545 DOI: 10.1053/j.gastro.2019.12.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 60] [Article Influence: 24.5] [Reference Citation Analysis]
106 Kim H, An J, Park J, Park S, Lim Y, Lee E. Magnetic Resonance Imaging Is Cost‐Effective for Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis. Hepatology 2019;69:1599-613. [DOI: 10.1002/hep.30330] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
107 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1948-5182')">Reference Citation Analysis]
108 Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? Curr Hepatol Rep 2017;16:137-45. [PMID: 29085770 DOI: 10.1007/s11901-017-0349-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
109 Weinfurtner K, Cho J, Ackerman D, Chen JX, Woodard A, Li W, Ostrowski D, Soulen MC, Dagli M, Shamimi-Noori S, Mondschein J, Sudheendra D, Stavropoulos SW, Reddy S, Redmond J, Khaddash T, Jhala D, Siegelman ES, Furth EE, Hunt SJ, Nadolski GJ, Kaplan DE, Gade TPF. Variability in biopsy quality informs translational research applications in hepatocellular carcinoma. Sci Rep 2021;11:22763. [PMID: 34815453 DOI: 10.1038/s41598-021-02093-6] [Reference Citation Analysis]
110 Chen H, Zhang Y, Li S, Li N, Chen Y, Zhang B, Qu C, Ding H, Huang J, Dai M. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res 2018;10:1947-58. [PMID: 30022853 DOI: 10.2147/CMAR.S167036] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
111 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
112 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
113 Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. Am J Gastroenterol 2020;115:1642-9. [PMID: 32530829 DOI: 10.14309/ajg.0000000000000715] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
114 Nathani P, Singal AG. Imaging and Biomarker Approaches to HCC Surveillance. Clin Liver Dis (Hoboken) 2021;17:401-4. [PMID: 34386203 DOI: 10.1002/cld.1066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Kim SY, Lim YS. Towards a New Horizon for Individualized Surveillance Tools in Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00498-5. [PMID: 33940226 DOI: 10.1016/j.cgh.2021.04.041] [Reference Citation Analysis]
116 Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Kim KW, Choi JI. Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1665. [PMID: 34574006 DOI: 10.3390/diagnostics11091665] [Reference Citation Analysis]
117 Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2019;28:531-538. [PMID: 30464023 DOI: 10.1158/1055-9965.epi-18-0281] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
118 Ganne-carrié N, Piscaglia F. Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk? Journal of Hepatology 2020;72:607-9. [DOI: 10.1016/j.jhep.2020.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Chong N, Schoenberger H, Yekkaluri S, Fetzer DT, Rich NE, Yokoo T, Gopal P, Manwaring C, Quirk L, Singal AG. Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. Aliment Pharmacol Ther 2022. [PMID: 35170052 DOI: 10.1111/apt.16779] [Reference Citation Analysis]
120 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
121 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
122 Lambrecht J, Porsch-Özçürümez M, Best J, Jost-Brinkmann F, Roderburg C, Demir M, Tacke F, Mohr R. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. J Clin Med 2021;10:3392. [PMID: 34362181 DOI: 10.3390/jcm10153392] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology 2019;292:390-7. [PMID: 31210614 DOI: 10.1148/radiol.2019190035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
124 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
126 Ye F, Huang W, Xue Y, Tang E, Wang M, Shi F, Wei D, Han Y, Chen P, Zhang X, Yu D. Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. J Hepatocell Carcinoma 2021;8:285-300. [PMID: 33948441 DOI: 10.2147/JHC.S306966] [Reference Citation Analysis]
127 Liu X, Ju W, Huo C, Zhang S, Wang X, Huang K. Overweight and Obesity as Independent Factors for Increased Risk of Hepatocellular Cancer-Related Mortality: A Meta-Analysis. J Am Coll Nutr 2021;40:287-93. [PMID: 32281914 DOI: 10.1080/07315724.2020.1751007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Hong SB, Kim DH, Choi SH, Kim SY, Lee JS, Lee NK, Choi JI. Inadequate Ultrasound Examination in Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3535. [PMID: 34441831 DOI: 10.3390/jcm10163535] [Reference Citation Analysis]
129 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
130 Marrero JA. Surveillance for Hepatocellular Carcinoma. Clin Liver Dis 2020;24:611-21. [PMID: 33012448 DOI: 10.1016/j.cld.2020.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
131 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
132 Schoenberger H, Chong N, Fetzer DT, Rich NE, Yokoo T, Khatri G, Olivares J, Parikh ND, Yopp AC, Marrero JA, Singal AG. Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00615-7. [PMID: 34119640 DOI: 10.1016/j.cgh.2021.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
133 da Silva PH, Gomes MM, de Matos CAL, de Souza E Silva IS, Gonzalez AM, Torres US, Salazar GMM, D'Ippolito G. HCC Detection on Surveillance US: Comparing Focused Liver Protocol Using US LI-RADS Technical Guidelines to a General Complete Abdominal US Protocol. J Ultrasound Med 2021. [PMID: 33463734 DOI: 10.1002/jum.15637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 147] [Article Influence: 131.0] [Reference Citation Analysis]
135 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Reference Citation Analysis]
136 Delacourt AT, Mehta AS. Liver Cancer (Current Therapies). Reference Module in Biomedical Sciences. Elsevier; 2021. [DOI: 10.1016/b978-0-12-820472-6.00007-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]